Skip to main content
Fig. 6 | Journal for ImmunoTherapy of Cancer

Fig. 6

From: Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells

Fig. 6

POG exerts a dose-dependent antitumour effect and improves the immunosuppressive microenvironment of tumours. a Tumour growth curves of B16-F10 tumour-bearing mice after POG treatment (n = 6). b Representative tumour images of control and POG-treated B16-F10 tumour-bearing mice (n = 6). c Body weight of B16-F10 tumour-bearing mice after POG treatment (n = 6). d Dotplots of live, CD45+CD11b+ cells in the tumours of control and POG-treated B16-F10 tumour-bearing mice (left panels) and proportion of PMN-MDSCs (CD11b+Ly6G+Ly6Clow) in bone marrow, spleen and CD45+ cells from tumours of control and POG-treated B16-F10 tumour-bearing mice (n = 6) (right charts). e Dotplots of live, CD45+ cells in the tumours of control and POG-treated B16-F10 tumour-bearing mice (left panels) and proportion of CD8 T-lymphocytes (CD3+CD8+) in spleens and CD45+ cells from tumours of control and POG-treated B16-F10 tumour-bearing mice (n = 6) (right charts). f-g Ability of PMN-MDSCs sorted from bone marrow (f) or tumours (g) of control and POG-treated B16-F10 tumour-bearing mice to inhibit CD8 T-lymphocyte proliferation (n = 6). h Proliferation of CD8 T-lymphocytes sorted from the spleens of control and POG-treated B16-F10 tumour-bearing mice (n = 6). i IFN-γ content of CD8 T-lymphocytes sorted from the spleens of control and POG-treated B16-F10 tumour-bearing mice (n = 6). The pooled data from three independent experiments are shown. All data are represented as the mean ± SD. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001

Back to article page